Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | Offering surgery to treatment-naïve patients with STS

Emily Z. Keung, MD, AM, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the importance of offering surgery to patients with soft tissue sarcomas (STS) earlier in the treatment course. Currently, clinical trials in STS most commonly enrol patients that have already received multiple lines of prior therapy. By resecting the tumor earlier in the disease course, it is possible to study its characteristics and design future clinical trials that will build upon findings from the Phase II trial (NCT03307616) assessing immune checkpoint blockade (ICB) therapy in patients with STS prior to surgery that demonstrated the positive prognostic impact of immune infiltrates in STS. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.